[1]
Godse K,Mehta A,Patil S,Gautam M,Nadkarni N, Omalizumab-A Review. Indian journal of dermatology. 2015 Jul-Aug; [PubMed PMID: 26288408]
[2]
Kaplan AP,Giménez-Arnau AM,Saini SS, Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017 Apr; [PubMed PMID: 27861988]
[3]
McKeage K, Omalizumab: a review of its use in patients with severe persistent allergic asthma. Drugs. 2013 Jul; [PubMed PMID: 23812924]
[6]
Plosker GL,Keam SJ, Omalizumab: a review of its use in the treatment of allergic asthma. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2008; [PubMed PMID: 18481901]
[7]
Thomson NC,Chaudhuri R, Omalizumab: clinical use for the management of asthma. Clinical medicine insights. Circulatory, respiratory and pulmonary medicine. 2012; [PubMed PMID: 22745565]
[8]
Clark JJ,Secrest AM,Hull CM,Eliason MJ,Leiferman KM,Gleich GJ,Powell DL, The effect of omalizumab dosing and frequency in chronic idiopathic urticaria: Retrospective chart review. Journal of the American Academy of Dermatology. 2016 Jun [PubMed PMID: 27185439]
[9]
Ledford DK, Omalizumab: overview of pharmacology and efficacy in asthma. Expert opinion on biological therapy. 2009 Jul; [PubMed PMID: 19527111]
[11]
Busse W,Buhl R,Fernandez Vidaurre C,Blogg M,Zhu J,Eisner MD,Canvin J, Omalizumab and the risk of malignancy: results from a pooled analysis. The Journal of allergy and clinical immunology. 2012 Apr; [PubMed PMID: 22365654]
[12]
Cruz AA,Lima F,Sarinho E,Ayre G,Martin C,Fox H,Cooper PJ, Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2007 Feb; [PubMed PMID: 17250692]
[14]
Vaglio A,Moosig F,Zwerina J, Churg-Strauss syndrome: update on pathophysiology and treatment. Current opinion in rheumatology. 2012 Jan; [PubMed PMID: 22089097]
[15]
Konstantinou GN,Chioti AG,Daniilidis M, Self-reported hair loss in patients with chronic spontaneous urticaria treated with omalizumab: an under-reported, transient side effect? European annals of allergy and clinical immunology. 2016 Sep [PubMed PMID: 27608479]
[16]
Noshela Ghazanfar M,Thomsen SF, Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab. European annals of allergy and clinical immunology. 2017 Nov [PubMed PMID: 29249138]
[17]
Kim HL,Leigh R,Becker A, Omalizumab: Practical considerations regarding the risk of anaphylaxis. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology. 2010 Dec 3; [PubMed PMID: 21129189]
[18]
Matera MG,Calzetta L,Rogliani P,Cazzola M, Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. Respiratory medicine. 2019 May 13; [PubMed PMID: 31136930]
[19]
Incorvaia C,Mauro M,Makri E,Leo G,Ridolo E, Two decades with omalizumab: what we still have to learn. Biologics : targets [PubMed PMID: 30464389]
[20]
Norman G,Faria R,Paton F,Llewellyn A,Fox D,Palmer S,Clifton I,Paton J,Woolacott N,McKenna C, Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health technology assessment (Winchester, England). 2013 Nov; [PubMed PMID: 24267198]